{"title": "Balance of two enzymes linked to pancreatic cancer survival", "title_detail": {"type": "text/plain", "language": null, "base": "https://www.sciencedaily.com/rss/health_medicine/cancer.xml", "value": "Balance of two enzymes linked to pancreatic cancer survival"}, "links": [{"rel": "alternate", "type": "text/html", "href": "https://www.sciencedaily.com/releases/2019/03/190320110642.htm"}], "link": "https://www.sciencedaily.com/releases/2019/03/190320110642.htm", "summary": "New research sets the stage for clinicians to potentially one day use levels of a pancreatic cancer patient's PHLPP1 and PKC enzymes as a prognostic, and for researchers to develop new therapeutic drugs that inhibit PHLPP1 and boost PKC as a means to treat the disease.", "summary_detail": {"type": "text/html", "language": null, "base": "https://www.sciencedaily.com/rss/health_medicine/cancer.xml", "value": "New research sets the stage for clinicians to potentially one day use levels of a pancreatic cancer patient's PHLPP1 and PKC enzymes as a prognostic, and for researchers to develop new therapeutic drugs that inhibit PHLPP1 and boost PKC as a means to treat the disease."}, "published": "Wed, 20 Mar 2019 11:06:42 EDT", "published_parsed": [2019, 3, 20, 15, 6, 42, 2, 79, 0], "id": "https://www.sciencedaily.com/releases/2019/03/190320110642.htm", "guidislink": false}